Simcere Signs an Exclusive License Agreement with JW Pharmaceutical for an Anti-Gout Drug Candidate URC-102 in China
Shots:
- JWP to receive up front- commercial milestones & royalties on sales in China. Simcere to get the license for clinical research- registration- and commercialization of URC-102 in China (including Hongkong & Macao)
- The collaboration will combine JWP’s expertise in new molecular entity drug discovery & development with Simcere expertise in clinical development and commercialization of therapies for rheumatic diseases
- URC-102 is a selective uric acid transporter (URAT-1) inhibitor- currently being evaluated in P-IIb for patients with gout in South Korea
Click here to read full press release/ article | Ref: PRNewswire | Image: TicaChina
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com